Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | COFO and Secretary | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 278,995 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 2,768 · Balance 278,995 F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026. F2: Includes 135,475 Unvested RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 523,749 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 523,749 F3: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026.
F2: Includes 135,475 Unvested RSUs.
F3: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2021 Filed Feb 12, 2021 00:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,262 | $74.66 | $94,218.40 |
DisclosureSEC source: 0001209191-21-009892 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 537,550 F3 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $74.17 to $75.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| February 07, 2021 Filed Feb 12, 2021 00:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009892 · doc4.xml · derivative · entry 5 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 4,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F6 · derivative.exercise_date: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F6 · derivative.expiration_date: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 07, 2021 Filed Feb 12, 2021 00:13 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009892 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 538,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,912 | $68.61 | $131,180.41 |
DisclosureSEC source: 0001209191-21-008103 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 534,562 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $68.44 to $68.90 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,509 | $67.90 | $441,941.57 |
DisclosureSEC source: 0001209191-21-008103 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 536,474 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $67.32 to $68.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 21:44 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,579 | $66.65 | $105,238.77 |
DisclosureSEC source: 0001209191-21-008103 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 542,983 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.26 to $67.25 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $70.86 | $0.00 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · derivative · entry 21 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-01-03 F23 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 4, 2022, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · derivative · entry 20 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F21 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F22 · derivative.exercise_date: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F22 · derivative.expiration_date: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,226 | $84.17 | $103,190.46 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 18 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 544,562 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F20 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $84.00 to $84.25 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,900 | $82.96 | $157,631.22 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 17 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 545,788 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F19 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $82.77 to $83.45 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,996 | $82.14 | $656,767.45 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 16 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 547,688 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F18 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $81.71 to $82.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,817 | $81.45 | $229,432.54 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 15 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 555,684 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F17 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $80.71 to $81.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,598 | $79.78 | $287,062.47 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 14 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 558,501 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F16 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $79.42 to $80.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,876 | $78.43 | $617,675.30 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 13 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 562,099 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F15 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $78.14 to $78.99 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,472 | $77.64 | $114,286.96 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 12 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 569,975 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F14 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $77.13 to $78.11 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 980 | $76.41 | $74,877.19 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 11 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 571,447 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F13 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $76.09 to $77.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 700 | $75.61 | $52,923.99 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 10 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 572,427 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F12 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $74.96 to $75.90 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,144 | $74.01 | $380,698.18 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 9 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 573,127 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $73.65 to $74.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,626 | $73.09 | $338,101.39 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 8 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 578,271 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $72.65 to $73.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,531 | $72.22 | $616,094.32 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 7 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 582,897 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.62 to $72.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,709 | $71.03 | $689,651.63 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 6 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 591,428 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.59 to $71.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,340 | $70.10 | $654,737.74 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 5 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 601,137 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.59 to $70.56 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,067 | $69.07 | $73,701.10 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 610,477 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $68.49 to $69.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 518 | $67.78 | $35,109.52 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 611,544 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $67.30 to $68.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,100 | $66.58 | $73,234.04 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 612,062 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.09 to $67.08 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:50 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,400 | $65.17 | $91,232.96 |
DisclosureSEC source: 0001209191-21-002345 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 613,162 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $65.02 to $65.40 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 00:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Tax withholdingCommon Stock | 1,954 | $32.88 | $64,247.52 |
DisclosureSEC source: 0001209191-20-048174 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 614,562 F3 · kind: Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $32.82 to $32.885 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 21, 2020 Filed Nov 30, 2020 23:11 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Tax withholdingCommon Stock | 1,954 | $32.88 | $64,247.52 |
DisclosureSEC source: 0001209191-20-060789 · doc4a.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 614,562 F3 · kind: Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $32.82 to $32.885 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 00:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 5,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048174 · doc4.xml · derivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,643 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F5 · derivative.exercise_date: 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. F5 · derivative.expiration_date: 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 00:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-048174 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 616,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 20, 2020 Filed Nov 30, 2020 23:11 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-060789 · doc4a.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 616,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047794 · doc4.xml · derivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 22:19 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,427 | $19.49 | $27,812.23 |
DisclosureSEC source: 0001209191-20-022240 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,662 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.44 to $19.53 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 136,000 | $0.00 Strike: $24.81 | $0.00 |
DisclosureSEC source: 0001209191-20-008925 · doc4.xml · derivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Stock · 136,000 shares Expires 2030-02-09 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 10, 2021, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 29,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008925 · doc4.xml · derivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,143 Underlying: Common Stock · 29,143 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on February 10, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on February 10, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 07, 2020 Filed Apr 1, 2020 22:15 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022236 · doc4a.xml · derivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Underlying: Common Stock · 4,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 07, 2020 Filed Apr 1, 2020 22:15 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 4,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-022236 · doc4a.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 22:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 3,121 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-19-059343 · doc4.xml · derivative · entry 9 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,937 Underlying: Common Stock · 3,121 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 22:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,121 | $18.00 | $56,178.00 |
DisclosureSEC source: 0001209191-19-059343 · doc4.xml · nonDerivative · entry 7 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,839 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.04 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 22:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 3,121 | $5.28 | $16,478.88 |
DisclosureSEC source: 0001209191-19-059343 · doc4.xml · nonDerivative · entry 6 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 22:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,656 | $18.00 | $47,808.00 |
DisclosureSEC source: 0001209191-19-059343 · doc4.xml · nonDerivative · entry 5 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 580,710 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.04 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 22:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 711 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-19-059343 · doc4.xml · derivative · entry 8 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,058 Underlying: Common Stock · 711 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 22:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 711 | $18.01 | $12,805.11 |
DisclosureSEC source: 0001209191-19-059343 · doc4.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,839 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 22:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 711 | $5.28 | $3,754.08 |
DisclosureSEC source: 0001209191-19-059343 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 22:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,012 | $18.01 | $18,226.12 |
DisclosureSEC source: 0001209191-19-059343 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 583,366 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.04 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| November 26, 2019 Filed Nov 26, 2019 22:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 229 | $18.02 | $4,126.58 |
DisclosureSEC source: 0001209191-19-058147 · doc4.xml · nonDerivative · entry 5 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 584,378 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 22:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 14,125 | $18.02 | $254,532.50 |
DisclosureSEC source: 0001209191-19-058147 · doc4.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 584,607 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.12 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 22:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 646 | $18.00 | $11,628.00 |
DisclosureSEC source: 0001209191-19-058147 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 598,732 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.01 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 21:05 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 5,129 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-19-054152 · doc4.xml · derivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,769 Underlying: Common Stock · 5,129 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 21:05 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,129 | $5.28 | $27,081.12 |
DisclosureSEC source: 0001209191-19-054152 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.